Corbus reports early obesity-drug weight loss, with CB1 safety questions unresolved

Corbus Pharmaceuticals reported on September 14 that its experimental obesity drug CRB-913 produced an estimated average weight reduction of 5% in the highest-dose group after 12 weeks, compared with no average change on placebo. The early findings support further investigation of a drug pathway whose development has repeatedly encountered psychiatric safety concerns.

The company disclosed the CANYON-1 results in a Securities and Exchange Commission filing. These are sponsor-reported findings from a Phase 1b study, with no established evidence yet of durable weight management or improved long-term health outcomes.

What the trial found

CANYON-1 enrolled 254 adults with obesity and without diabetes at 15 U.S. sites. Participants were randomly assigned to three active-treatment groups or placebo in a double-blind design, meaning treatment assignments were concealed. Treatment lasted 12 weeks, followed by four weeks of observation.

Estimated average weight reductions were 2.8%, 3.3% and 5.0% across the active groups. Corbus reported statistically significant differences from placebo for each group. The estimates came from a repeated-measures statistical model; they should not be interpreted as the weight change every participant experienced.

A different metabolic target

CRB-913 is an oral small molecule that reduces signaling through the cannabinoid-1 receptor, or CB1. Corbus describes it as designed to act mainly outside the brain. This approach could offer another route for obesity-drug development beyond medicines targeting incretin hormones such as GLP-1.

The company's September presentation says a Phase 2 monotherapy study is expected to begin in the first half of 2027. That remains a development plan. Restricting a drug's access to the brain is a design strategy whose clinical safety implications require testing over adequate periods and in sufficiently large populations.

Why psychiatric safety matters

The history of CB1-directed treatment makes this more than a routine tolerability question. In October 2008, the European Medicines Agency recommended suspending rimonabant, marketed as Acomplia, after concluding that its benefits no longer outweighed its risks. The agency identified approximately twice the risk of psychiatric disorders compared with placebo. Its European marketing authorization was withdrawn in January 2009.

More recent evidence also illustrates the challenge. A peer-reviewed Phase 2a trial of another CB1 inverse agonist, monlunabant, published online in September 2025, randomized 243 adults with obesity and metabolic syndrome. It found greater weight loss than placebo over 16 weeks, alongside adverse-event withdrawals that increased across the active-dose groups.

Those withdrawal rates ranged from 13% to 42%, compared with none on placebo, and were driven by nausea, anxiety, diarrhea, irritability and sleep disorder. The investigators concluded that lower doses warranted further study. These findings concern a different molecule and cannot establish CRB-913's risks, but they explain why weight loss alone is insufficient to evaluate this approach.

What remains unresolved

Corbus's presentation compares aspects of CRB-913 tolerability with results from separate obesity-drug studies. It explicitly cautions that these observations are not head-to-head comparisons. Different populations, treatment durations and methods for recording adverse events can make such comparisons misleading.

For healthspan research, the next questions extend beyond changes on a scale: whether weight reductions persist, whether treatment remains tolerable, and whether benefits translate into better function or fewer disease events. A short early-phase trial cannot settle those questions or reliably exclude uncommon harms.

The practical significance is a new clinical signal for an investigational metabolic treatment. Establishing its value will require fuller reporting and larger, longer trials that evaluate benefit and harm together.